Skip to main content

Table 2 Showing the MFI log10 transformed antibodies to HPV-16/18 and other hrHPV types among vaccinated and unvaccinated girls

From: The levels of anti-HPV16/18 and anti-HPV31/33/35/45/52/58 antibodies among AS04-adjuvanted HPV16/18 vaccinated and non-vaccinated Ugandan girls aged 10–16 years

 

Vaccinated month 18 (n = 207)

Unvaccinated (n = 197)

 
 

MFI (95% CI)

MFI (95% CI)

P-value

HPV16

4691.4(4438.1-4957.9)

218.5(189.7-251.6)

<0.001

HPV18

1615.5(1469.6-1775.8)

103.3(88.1-121.3)

<0.001

HPV31

844.9(750.1-951.5)

251(211.3-298.3)

<0.001

HPV33

444(399.3-493.6)

245.7(215.2-280.5)

<0.001

HPV35

752(661.3-854.9)

185.2(158.7-216.1)

<0.001

HPV45

634.6(563.2-715.2)

127.6(111.7-145.7)

<0.001

HPV52

640.2(570.4-718.5)

260.6(231–294)

<0.001

HPV58

404.9(364.6-449.5)

229.1(207.3-253.3)

<0.001

  1. Comparing means of MFI log10 transformed antibodies to HPV-16/18 and other hrHPV types among vaccinated and unvaccinated girls. The mean of the MFI levels to other non vaccine hrHPV-31, 33, 35, 45, 52 and 58 were all significantly higher among the vaccinated than the unvaccinated girls when compared antibodies at month 18 post vaccination.
Back to article page

Infectious Agents and Cancer

ISSN: 1750-9378

Contact us